Skip to main content

Table 3 Change from Baseline in MADRS and Odds Ratio for Response (≥ 50% improvement in MADRS)

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

PLO −1.08 [−3.26, 1.10] −2.29 [−3.47, −1.09] −4.57 [−5.92, −3.16] −4.80 [−5.93, − 3.72] − 1.34 [− 3.29, 0.67] −4.71 [−6.98, − 2.41]
1.11 [0.80, 1.51] ARI − 1.21 [− 3.70, 1.29] −3.49 [− 6.07, −0.92] −3.72 [− 6.21, − 1.28] −0.27 [− 3.24, 2.71] −3.63 [− 6.78, − 0.50]
1.47 [1.17, 1.82] 1.35 [0.90, 1.95] CAR −2.29 [− 4.09, − 0.46] −2.52 [− 4.11, − 0.92] 0.94 [− 1.34, 3.27] −2.42 [− 5.01, 0.14]
1.56 [1.20, 2.01] 1.44 [0.94, 2.14] 1.08 [0.76, 1.51] OLA −0.23 [−2.05, 1.53] 3.23 [0.83, 5.66] − 0.13 [− 2.82, 2.50]
2.09 [1.74, 2.49] 1.92 [1.32, 2.71] 1.44 [1.08, 1.91] 1.36 [0.98, 1.84] QUE 3.46 [1.24, 5.76] 0.10 [−2.44, 2.61]
1.07 [0.77, 1.46] 0.99 [0.61, 1.50] 0.74 [0.50, 1.08] 0.70 [0.45, 1.03] 0.52 [0.35, 0.74] ZIP −3.36 [− 6.38, − 0.39]
2.58 [1.67, 3.81] 2.38 [1.38, 3.85] 1.78 [1.08, 2.77] 1.68 [0.99, 2.65] 1.25 [0.78, 1.90] 2.47 [1.41, 3.98] LUR
  1. Note: MADRS results are on the top-right and response results are on the bottom-left. Results give the mean change and odds ratio [95% credible interval]. In the top-right comparisons, the row treatment is the reference category. In the bottom-left, the column treatment is the reference category. Response was defined as ≥50% improvement in MADRS
  2. Abbreviations: MADRS Montgomery–Åsberg Depression Rating Scale, PLO Placebo, ARI Aripiprazole, CAR Cariprazine, LUR Lurasidone, OLA Olanzapine, QUE Quetiapine, ZIP Ziprasidone